© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90651 refers to the Human Papillomavirus (HPV) vaccine, specifically the nonavalent (9vHPV) formulation. This vaccine is designed for intramuscular administration and is available in both 2-dose and 3-dose schedules. Vaccines, unlike immune globulins that provide temporary immunity, work by stimulating the recipient's immune system to recognize and combat specific pathogens. The HPV vaccine targets a group of over 100 viruses, some of which are responsible for benign warts, while others are associated with higher risks of developing cervical cancer. By introducing a modified version of these viruses, the vaccine prompts the immune system to produce antibodies, thereby establishing long-term immunity. It is crucial for the vaccine to be administered before the individual is exposed to the virus to effectively prevent infection and its potential long-term consequences, such as cancer. The 9vHPV vaccine covers nine HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58, which are linked to various cancers globally. This code specifically reports the supply of the nonavalent vaccine, distinguishing it from other HPV vaccines, such as the quadrivalent (4vHPV) and bivalent (2vHPV) vaccines, which target fewer HPV types.
© Copyright 2025 Coding Ahead. All rights reserved.
The Human Papillomavirus vaccine (CPT® Code 90651) is indicated for the prevention of infections caused by specific types of human papillomavirus. The following conditions and circumstances warrant the administration of this vaccine:
The administration of the Human Papillomavirus vaccine (CPT® Code 90651) involves the following procedural steps:
After the administration of the Human Papillomavirus vaccine (CPT® Code 90651), patients are typically advised to remain in the healthcare setting for a brief observation period, usually around 15 minutes, to monitor for any immediate allergic reactions. Common post-vaccination care includes advising the patient to apply a cool compress to the injection site to alleviate any discomfort or swelling. Patients may experience mild side effects such as soreness at the injection site, low-grade fever, or fatigue, which are generally self-limiting. It is important to inform patients about the need for follow-up doses if a multi-dose schedule is recommended, and to encourage them to report any unusual or severe reactions to their healthcare provider. Additionally, patients should be educated on the importance of completing the vaccination series to ensure optimal protection against HPV-related diseases.
| Short Descr | 9VHPV VACCINE 2/3 DOSE IM | Medium Descr | 9VHPV VACC 2/3 DOSE SCHED IM USE | Long Descr | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Berenson-Eggers TOS (BETOS) | O1G - Immunizations/Vaccinations | MUE | 1 |
| JZ | Zero drug amount discarded/not administered to any patient | 25 | Significant, separately identifiable evaluation and management service by the same physician or other qualified health care professional on the same day of the procedure or other service: it may be necessary to indicate that on the day a procedure or service identified by a cpt code was performed, the patient's condition required a significant, separately identifiable e/m service above and beyond the other service provided or beyond the usual preoperative and postoperative care associated with the procedure that was performed. a significant, separately identifiable e/m service is defined or substantiated by documentation that satisfies the relevant criteria for the respective e/m service to be reported (see evaluation and management services guidelines for instructions on determining level of e/m service). the e/m service may be prompted by the symptom or condition for which the procedure and/or service was provided. as such, different diagnoses are not required for reporting of the e/m services on the same date. this circumstance may be reported by adding modifier 25 to the appropriate level of e/m service. note: this modifier is not used to report an e/m service that resulted in a decision to perform surgery. see modifier 57 for significant, separately identifiable non-e/m services, see modifier 59. | CR | Catastrophe/disaster related | GA | Waiver of liability statement issued as required by payer policy, individual case | GC | This service has been performed in part by a resident under the direction of a teaching physician | GX | Notice of liability issued, voluntary under payer policy | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | GZ | Item or service expected to be denied as not reasonable and necessary | PN | Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital | PO | Excepted service provided at an off-campus, outpatient, provider-based department of a hospital | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study | SA | Nurse practitioner rendering service in collaboration with a physician | SK | Member of high risk population (use only with codes for immunization) | SL | State supplied vaccine | UC | Medicaid level of care 12, as defined by each state | UD | Medicaid level of care 13, as defined by each state | X1 | Continuous/broad services: for reporting services by clinicians, who provide the principal care for a patient, with no planned endpoint of the relationship; services in this category represent comprehensive care, dealing with the entire scope of patient problems, either directly or in a care coordination role; reporting clinician service examples include, but are not limited to: primary care, and clinicians providing comprehensive care to patients in addition to specialty care | XE | Separate encounter, a service that is distinct because it occurred during a separate encounter |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2018-01-01 | Changed | First appearance of change in code book |
| 2017-07-01 | Changed | Revise description to include the new FDA approved 2-dose schedule. |
| 2017-01-01 | Changed | Code description changed. |
| 2016-01-01 | Changed | Description Changed |
| 2015-01-01 | Added | Added. FDA approval granted December 10, 2014 |
| 1991-12-31 | Deleted | Code deleted. |
Get instant expert-level medical coding assistance.